Roux-en-Y胃肠道重建改善非肥胖性糖尿病胃癌患者的糖脂代谢

目的 观察Roux-en-Y胃肠道重建对非肥胖件糖尿病胃癌患者血糖和血脂代谢的影响.方法 非肥胖性糖尿病胃癌患者57例行根治性远端胃切除术,其中35例行Roux-en-Y胃肠道重建,22例行Billroth Ⅰ式胃肠道重建.观察手术前、手术后3个月和6个月两组体质量指数、糖化血红蛋白、空腹血糖、胰岛素、C肽、甘油三酯、总胆固醇、高密度脂蛋白和低密度脂蛋白含量的变化,并检测口服葡萄糖后2 h血糖、胰岛素和C肽的变化.结果 手术前两组各检测指标之间相比差异均无统计学意义(P＞0.05).手术后两组体质量指数变化之间相比差异无统计学意义(P＞0.05);术前、手术后3个月和6个月Roux-en-Y胃肠道重建组空腹血糖为(9.3±0.9)mmol/L比(7.2±2.1)mmoL/L比(7.1±0.8)mmoL/L,P=0.000;糖化血红蛋白为(9.2±1.2)%比(7.3±1.2)%比(7.2±1.1)%,P=0.000;空腹甘油三酯为(3.21±0.88)mmoL/L比(2.12±0.97)mmol/L比(2.02±0.09)mmol/L,P=0.000;空腹总胆固醇为(6.4±1.9)mmol/L比(4.3±1.0)mmol/L比(4.1±1.0)mmol/L,P=0.000;空腹低密度脂蛋白为(3,61±1.05)mmol/L比(2.77±0.68)mmol/L比(2.71±0.18)mmol/L,P=0.000;2 h血糖为(17.6±2.5)mmoL/L比(12.1±1.9)mmoL/L比(11.6±2.3)mmol/L,P=0.000,含量较手术前明显下降(P＜0.01).空腹胰岛素为(98±11)pmol/L比(120±9)pmoL/L比(122±8)pmol/L,P=0.000;空腹C肽为(0.21±0.08)mmol/L比(0.30±0.01)mmol/L比(0.30±0.01)mmol/L,P=0.000;空腹高密度脂蛋白为(1.08±0.10)mmol/L比(1.61±0.34)mmol/L比(1.62±0.09)mmol/L,P=0.000;2 h胰岛素为(410±19)pmol/L比(446±19)pmol/L比(459±18)pmol/L,P=0.000;2 h C肽为(0.87±0.17)mmol/L比(1.22±0.14)mmol/L比(1.19±0.15)mmol/L,P=0.000.Billroth Ⅰ式胃肠道重建组糖化血红蛋白为(9.2±1.2)%比(8.4±1.6)%比(8.3±1.1)%,P=0.046.结论 Roux-en-Y胃肠道重建术可改善非肥胖性糖尿病胃癌患者血糖和血脂代谢,且与体质量指数变化无关.

Effects of gastric bypass on carbohydrate and lipid metabolism in non-obese patients with type 2 diabetes and gastric carcinoma

Objective To observe the effects of Roux-en-Y gastrointestinal reconstruction(RYGR) on carbohydrate and lipid metabolism in non-obese patients with type 2 diabetes and gastric carcinoma.Methods Fifty seven gastric cancer cases who underwent radical distal gastrectomy were studied and among them 35 patients had Roux-en-Y gastrointestinal reconstruction (RYGR group) and 22 had Billroth-Ⅰ gastrointestinal reconstruction (B-I GR group).Both groups were subjected to the measuring of preoperative and postoperative third,sixth months values of body mass index (BMI),glycosylated hemoglobin (GHbA1c),fasting glucose (FPG),fasting insulin (Flns) and C-peptide (FC-P),oral glucose tolerance (OGTT) including 2 hour insulin (2hIns) and C-peptide (2hC-P),plasma levels of total cholesterol (TC),triglycerides (TG),high density lipoprutein (HDL-c) and low density lipoprotein (LDL-c).Result There was no significant difference between the two groups in preoperative values (P＞0.05).There was no statistically significant difference in BMI values measured postoperatively (P ＞ 0.05).In RYGR group,preoperative FPG and that of third and sixth month postoperatively was (9.3±0.9) mmol/L vs.(7.2±2.1) mmol/L vs.(7.1±0.8) mmol/L,P=0.000,GHbAlc was (9.2±1.2)% vs.(7.3±1.2)% vs.(7.2±1.1)%,P=0.000,TG was (3.21±0.88) mmol/L vs.(2.12±0.97) mmol/L vs.(2.02±0.09) mmol/L,P =0.000,TC was (6.4±1.9) mmol/L vs.(4.3±1.0) mmol/L vs.(4.1±1.0) mmol/L,P =0.000 and LDL-c was (3.61±1.05) mmol/L vs.(2.77±0.68) mmol/L vs.(2.71±0.18)mmool/L,P=0.000,2 hour glucose after OGTT(2hPG) was (17.6±2.5) mmol/L vs.(12.1±1.9) mmol/L vs.(11.6±2.3) mmol/L,P = 0.000.Levels of FIns was (98±11) pmol/L vs.(120±9)pmol/L vs.(122±8) pmol/L,P =0.000,FC-P was (0.21±0.08) mmol/L vs.(0.30±0.01) mmol/L vs.(0.30±0.01) mmol/L,P=0.000,HDL-c was (1.08±0.10) mmol/L vs.(1.61±0.34) mmol/L vs.(1.62±0.09) mmol/L,P = 0.000,2 h Ins was (410±19) pmol/L vs.(446±19) pmol/L vs.(459±18) pmol/L,P = 0.000 and 2 h C-P was (0.87±0.17) mmol/L vs.(1.22±0.14) mmol/L vs.(1.19±0.15) mmol/L,P =0.000.In B-I GR group,preoperative and third and sixth postoperative month values of GHbA1c were (9.2±1.2)% vs.(8.4±1.6)% vs.(8.3±1.1)%,P =0.046.Conclusion Roux-en-Y gastric bypass can significantly improve the metabolism of carbohydrate and lipid in non-obese patients with type 2 diabetes and gastric carcinoma,and the effects are not related with postoperative weight loss.